Boosting endocannabinoids reduced fear in traumatized rats through CB2 receptors, not CB1 | Research

The takeaway

In rats exposed to predator stress, the endocannabinoid-boosting drug JZL184 reduced persistent fear behaviors, but surprisingly through CB2 receptors rather than the expected CB1 receptors, with CB2 gene expression upregulated in the prefrontal cortex after stress.

PTSD researchers, anxiety pharmacologists, and neuroscientists studying the endocannabinoid system.

Fear reduction via CB2 (not CB1); CB2 upregulated by stress

What the researchers found

JZL184 (MGL inhibitor) dose-dependently suppressed predator-induced fear (ED50 = 4 mg/kg). This effect was blocked by the CB2 antagonist AM630 but not by the CB1 antagonist rimonabant. CB2 mRNA was elevated in the prefrontal cortex 7 days after predator stress. A direct CB2 agonist also reduced fear but only in stressed animals.

Why it matters

This challenges the dominant assumption that endocannabinoid-based anxiety treatments work through CB1 receptors. The CB2 finding opens a new therapeutic target for PTSD that could avoid the psychoactive side effects associated with CB1 activation.

The numbers in context

JZL184 ED50 = 4 mg/kg. AM630 (CB2 antagonist) blocked the effect; rimonabant (CB1 antagonist) did not. JWH133 (CB2 agonist) reduced fear at 0.3-3 mg/kg but only in stressed rats. CB2 mRNA elevated in prefrontal cortex after stress.

How the study worked

Rats were exposed to TMT (predator odor) to induce persistent fear, then tested 7 days later in the elevated plus maze. JZL184, KML29 (MGL inhibitors), and JWH133 (CB2 agonist) were tested with and without receptor antagonists.

What this study cannot tell us

Animal model of fear may not fully capture human PTSD. TMT-induced fear is an innate response, not learned trauma. CB2 expression was measured only in the prefrontal cortex.

How to read the evidence

Moderate: well-controlled pharmacological study with multiple receptor antagonist controls, though limited to animal model.

When this study was published

Published in 2020 in Neuropsychopharmacology.

The bigger picture

The finding that stress itself upregulates CB2 in the prefrontal cortex suggests the brain may be mounting an endogenous protective response that can be therapeutically enhanced, specifically in stressed individuals.

Questions still open

Would CB2-selective drugs work for human PTSD without psychoactive effects? Why does CB2 activation only reduce fear in stressed animals? Could CB2 expression serve as a biomarker for stress-related disorders?

Common questions

Why is the CB2 finding surprising?

Most endocannabinoid research on anxiety has focused on CB1 receptors, which are abundant in the brain. CB2 was traditionally thought to be mainly in the immune system. This study shows CB2 in the brain plays a direct role in fear regulation after stress.

Could this lead to PTSD treatments without getting high?

Potentially. CB2-targeted drugs would not be expected to produce the intoxicating effects associated with CB1 activation. The fact that CB2 agonists only worked in stressed (not unstressed) animals also suggests targeted therapy may be possible.

Read the original research

Cannabinoid CB2 receptors mediate the anxiolytic-like effects of monoacylglycerol lipase inhibition in a rat model of predator-induced fear.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 45(8), 1330-1338

View on PubMed ↗Publisher’s paper ↗

Citation

Ivy, Devon; Palese, Francesca; Vozella, Valentina; Fotio, Yannick; Yalcin, Aylin; Ramirez, Gina; Mears, David; Wynn, Gary; Piomelli, Daniele. (2020). Cannabinoid CB2 receptors mediate the anxiolytic-like effects of monoacylglycerol lipase inhibition in a rat model of predator-induced fear.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 45(8), 1330-1338. https://doi.org/10.1038/s41386-020-0696-x